Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological
 therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or
 lymphoproliferative disease.
Inclusion Criteria:

 -  Pathologically documented EBV antigen positive lymphoproliferative disease, lymphoma,
 or other EBV-associated malignancy OR

 -  Severely immunocompromised patients who develop blood levels of EBV DNA exceeding 500
 copies/ml DNA, and are therefore at high risk for developing an EBV LPD

 It is expected that five types of patients afflicted with EBV-associated lymphomas or
 lymphoproliferative diseases will be referred and will consent to participate in this
 trial. These are:

 1. Patients developing or at risk for EBV lymphomas or lymphoproliferative disorders
 following an allogeneic marrow transplant.

 2. Patients developing or at risk for EBV lymphomas or lymphoproliferative disorders
 following an allogeneic organ transplant.

 3. Patients with AIDS developing EBV lymphomas or lymphoproliferative diseases as a
 consequence of the profound acquired immunodeficiency induced by HIV.

 4. Patients who develop EBV lymphomas or lymphoproliferative diseases as a consequence of
 profound immunodeficiencies associated with a congenital immune deficit or acquired as
 a sequela of anti-neoplastic or immunosuppressive therapy.

 5. Patients who develop other EBV-associated malignancies without pre-existing immune
 deficiency, including: EBV+ Hodgkin's and Non- Hodgkin's disease, EBV+ nasopharyngeal
 carcinoma, EBV+ hemophagocytic lymphohistiocytosis, or EBV+ leiomyosarcoma.

 Exclusion Criteria:

 The following patients will be excluded from this study:

 -  Moribund patients who, by virtue of heart, kidney, liver, lung, or neurologic
 dysfunction not related to lymphoma, are unlikely to survive the 6-8 weeks required
 for in vitro generation and expansion of the EBV-specific T cells to be used for
 therapy and the subsequent 3 weeks required to achieve an initial assessment of the
 effects of infusions of EBV-specific T cells.

 -  Pregnancy does not constitute a contraindication to infusions of EBV-specific T cells.